Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
نویسندگان
چکیده
Abstract To assess the predictive and prognostic aim of interim end-treatment 18 F-fluorocholine PET/CT (FCH-PET/CT) 99m Tc-methilen diphosphonate bone scintigraphy (BS) in patients with castration-resistant prostate cancer metastases (CRPC-BM) treated Radium 223 dichloride ( Ra). Prospective multicentre ChoPET-Rad study including 82 CRPC-BM. Baseline, after 3 (interim) 6 doses (end-treatment) BS FCH were performed who meet criteria. Clinical variables, imaging clinical progression obtained their association free survival (PFS), overall (OS) was studied. Agreement between response assessed using Kappa (K) analysis. Median PFS OS 16 months, respectively. weak (K: 0.28; p = 0.004). No agreement observed diagnostic studies. Interim related to (p 0.011 < 0.001, respectively). Therapeutic failure showed 0.037 0.008, good predictors biochemical Ra. or adverse factors for OS.
منابع مشابه
Radium 223 dichloride for prostate cancer treatment
Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichlorid...
متن کاملTreatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
Radium-223 dichloride (Ra-223) is the first α-particle emitting radiopharmaceutical to be approved for the treatment of patients with castration-resistant prostate cancer and associated bone metastases, and the first bone-targeting agent to significantly improve patient overall survival whilst reducing pain and the symptomatic skeletal events (SSEs) associated with bone metastases. Ra-223 exhib...
متن کاملNursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
BACKGROUND Radium-223 dichloride, or radium-223, is a first-in-class alpha emitter that selectively targets bone metastases with high-energy, short-range alpha particles and is approved for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. Nurses are essential in educating patients about radium-223....
متن کاملThe safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
INTRODUCTION A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for men with CRPC. The α-emitting radiopharmaceutical radium-223 dichloride has been shown to improve overall survival, time to symptomatic skeletal events (SSEs) and quality of life in CR...
متن کاملUtility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223
A 76-year-old man with symptomatic bone metastases from castrationresistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostate-specific antigen (PSA), doubling every month during Ra-223 therapy, suggested a PSA flare or rel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scientific Reports
سال: 2021
ISSN: ['2045-2322']
DOI: https://doi.org/10.1038/s41598-021-86759-1